Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.

Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Abstract Text:

Sandeep Vaishnavi,Syed Alamy,Wei Zhang,Kathryn M Connor,Jonathan R T Davidson,Sandeep Vaishnavi,Syed Alamy,Wei Zhang,Kathryn M Connor,Jonathan R T Davidson,

Social anxiety disorder (SAD) is one of the most common anxiety disorders. Reports have suggested an effect of the atypical antipsychotic quetiapine in anxiety disorders. Given these considerations, we conducted a controlled trial of quetiapine monotherapy in SAD. Fifteen patients were randomized to quetiapine (up to 400 mg/day) or placebo for 8 weeks. The Brief Social Phobia Scale (BSPS) and the Clinical Global Impression of Improvement Scale (CGI-I) were the primary outcome measures, while the Social Phobia Inventory (SPIN) and the Sheehan Disability Inventory (SDI) were secondary measures. There was no significant difference on the BSPS score at endpoint between the quetiapine and placebo groups. There was a significant time effect but not a significant time x treatment group interaction, indicating that both the quetiapine and placebo patients did better over the course of the trial. 20% of the quetiapine patients had a 50% or greater drop in BSPS score at the end of the trial compared to baseline, while 0% had such a drop in the placebo group. There was no significant difference in responders (CGI-I score of 1 or 2) versus non-responder (CGI-I score of 3 or more) across the groups. However, 40% of quetiapine patients and 0% of the placebo patients showed much or very much improvement on the CGI-I. The Number Needed to Treat (NNT) to be a responder on the CGI-I was 3. Significant time effects were noted for the SPIN and SDI, as well as a significant time x treatment effect in favor of quetiapine on the SPIN. Additionally, quetiapine showed a large effect size on the SPIN.

Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Publishing Authors By Initials

S Vaishnavi,S Alamy,W Zhang,KM Connor,JR Davidson,S Vaishnavi,S Alamy,W Zhang,KM Connor,JR Davidson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Progress in neuro-psychopharmacology & biological

VOLUME: 31

Page Numbers: 1464-9

Journal Abbreviation: Prog. Neuropsychopharmacol. Bi

ISSN: 0278-5846

DAY: 4

MONTH: 07

YEAR: 2007

Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8211617

Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.

AFFILIATION: Duke University Medical Center, Department of Psychiatry, Room 4082A, Duke South, Yellow Zone, Durham, NC 27710, USA. sandeep.vaishnavi@gmail.com

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Prog Neuropsychopharmacol Biol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study Related Publications

• (Pro)Insulin processing: a historical perspective.
• Adjuvant hormonal therapy for premenopausal women with breast cancer.
• Amygdala volume and nonverbal social impairment in adolescent and adult males with autism.
• Ceramide structural features required to stimulate ABCA1-mediated cholesterol efflux to apolipoprotein A-I.
• Comparing tongue shapes from ultrasound imaging using smoothing spline analysis of variance.
• Consistent relationships between sensory properties of savory snack foods and calories influence food intake in rats.
• Course of depressive symptoms and medication adherence after acute coronary syndromes: an electronic medication monitoring study.
• Depression vulnerabilities in patients with different levels of depressive symptoms after acute coronary syndromes.
• Difference spectrophotometric assay of 1,2-diphenolic drugs in pharmaceutical formulations - I. Boric acid reagent.
• Difference spectrophotometric assay of 1,2-diphenolic drugs in pharmaceutical formulations -III. The simultaneous assay of levodopa and benserazide.
• Effects of stimulus level on the speech perception abilities of children using cochlear implants or digital hearing AIDS.
• Event-related functional magnetic resonance imaging measures of neural activity to positive social stimuli in pre- and post-treatment depression.
• Granular cell tumour of the bile duct mimicking distal cholangiocarcinoma: one case report and review of the literature.
• High regulatory gene use in sea urchin embryogenesis: Implications for bilaterian development and evolution.
• Hindgut specification and cell-adhesion functions of Sphox11/13b in the endoderm of the sea urchin embryo.
• Identification and characterization of homeobox transcription factor genes in Strongylocentrotus purpuratus, and their expression in embryonic development.
• Kava in generalized anxiety disorder: three placebo-controlled trials.
• Mechanistic possibilities in MauG-dependent tryptophan tryptophylquinone biosynthesis.
• POLARIZED ABSORPTION SPECTRA OF SINGLE CRYSTALS OF 1-METHYLTHYMINE, 9-METHYLADENINE, AND THEIR HYDROGEN-BONDED COMPLEX.
• Peripartum changes in the bovine placenta related to fetal membrane retention.
• Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes.
• Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes.
• Pharmacist staffing, technology use, and implementation of medication safety practices in rural hospitals.
• Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study.
• Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice.
• RNA polymerase III transcribes human microRNAs.
• Silencing estrogen receptor alpha in breast cancer cells.
• The C2H2 zinc finger genes of Strongylocentrotus purpuratus and their expression in embryonic development.
• The temperature dependence of derivative ultraviolet absorption spectra.
• What else can we do to combat stigma?